Live Breaking News & Updates on Enroll Patients

Stay updated with breaking news from Enroll patients. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update


Share:
Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS) in Greater China
National Ethics Committee Approval for GPS Phase 3 REGAL Study Received in Greece
Preparations Underway to Activate Clinical Trial Sites and Enroll Patients in the REGAL Study in France, Germany and Greece by End of Second Quarter 2021
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ( SELLAS or the Company ), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended March 31, 2021 and provided a business update. ....

United States , Caitlin Kasunich Raquel Cona , Angelos Stergiou , Valter Pinto Allison Soss , D Medicines For Development , National Ethics Committee Approval , National Ethics Committee , Strategic Communications , Life Sciences Group Inc , European Union , Memorial Sloan Kettering Cancer Center , Milestone Payment , License Revenue Under Exclusive Agreement , Ethics Committee Approval , Activate Clinical Trial Sites , Enroll Patients , Second Quarter , Sciences Group , Greater China , Chief Executive Officer , First Quarter , Annual Report , Months Ended March , ஒன்றுபட்டது மாநிலங்களில் , வால்டர் பிண்டோ அல்லிசன் சோஸ்ஸ் , தேசிய நெறிமுறைகள் குழு ,